Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medical liability bill

This article was originally published in The Tan Sheet

Executive Summary

Language included in a House Energy & Commerce Committee report on the "Help Efficient, Accessible, Low-Cost, Timely Healthcare (HEALTH) Act of 2003" specifies that liability protection for manufacturers of FDA-approved drugs includes OTC products. HR 5, which passed the House March 13, states punitive damages may not be awarded against manufacturers of FDA-approved products unless parties involved in the evolution of the product "cause harm by failing to comply with a specific requirement" of the FD&C Act. OTCs compliant with NDAs, final monographs or tentative final monographs before they are finalized should not be precluded from liability protection, committee's report notes. CHPA lobbied for inclusion of language...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS095238

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel